Scarica l'app Stockscreener
456.94
0.13%
-1.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$458.05
Aprire:
$454.62
Volume 24 ore:
281.66K
Relative Volume:
0.19
Capitalizzazione di mercato:
$116.42B
Reddito:
$12.07B
Utile/perdita netta:
$3.95B
Rapporto P/E:
29.80
EPS:
15.3349
Flusso di cassa netto:
$3.19B
1 W Prestazione:
-2.54%
1M Prestazione:
-4.08%
6M Prestazione:
+19.40%
1 anno Prestazione:
-10.34%
Intervallo 1D:
$453.69
$458.98
Intervallo di 1 settimana:
$449.75
$476.17
Portata 52W:
$362.50
$513.98
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
458.29 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
743.79 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
685.02 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ALNY
Alnylam Pharmaceuticals Inc
|
315.78 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
284.00 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
My Top 3 Drug Stocks for March 2026 - The Motley Fool
CIBC Bancorp USA Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals (VRTX) Offering Value After Recent Share Price Pullback? - simplywall.st
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - AOL.com
RBC Capital reiterates Vertex stock rating on competitive concerns - Investing.com
Swiss Life Asset Management Ltd Buys 6,045 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Groupama Asset Management Trims Stake in Vertex Pharmaceuticals - National Today
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $550 From $515, Maintains Overweight Rating - marketscreener.com
Argus Adjusts PT on Vertex Pharmaceuticals to $520 From $475, Maintains Buy Rating - marketscreener.com
Mirabella Financial Services LLP Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Groupama Asset Managment Sells 17,916 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Stock In Shambles: Down 9.5% With 6-Day Losing Streak - Trefis
Danske Bank A S Makes New $64.42 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by AIA Group Ltd - MarketBeat
Vertex Pharmaceuticals (VRTX) Upgraded to Buy by Maxim Group | V - GuruFocus
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals (VRTX) Gains Amid Optimistic Outlook and Upgrade - GuruFocus
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Buy" at Maxim Group - MarketBeat
Vertex Pharmaceuticals Stock Slides 7.3% With A 5-Day Losing Spree - Trefis
Vertex Pharmaceuticals Stock Plummets -7.3% With 5-Day Losing Streak - Trefis
Vertex Pharmaceuticals Incorporated $VRTX is Provident Investment Management Inc.'s 4th Largest Position - MarketBeat
Fierce Biotech Layoff Tracker 2026: Gossamer lays off 48%; Bicycle deflates - Fierce Biotech
Physician Views Preview: How clinically meaningful are Vertex's Phase III data for povetacicept? - FirstWord Pharma
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 2,329 Shares - MarketBeat
Vertex Pharmaceuticals EVP and CMO Carmen Bozic Sells Shares - TradingView
Vertex (VRTX) EVP and CMO Carmen Bozic sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan
Top Biotech Stocks To Follow TodayMarch 17th - MarketBeat
Mirabella Financial Services LLP Has $2.10 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Focus Partners Wealth Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bamco Inc. NY Trims Stake in Vertex Pharmaceuticals - National Today
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bamco Inc. NY - MarketBeat
Bank of Nova Scotia Buys 36,643 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by California Public Employees Retirement System - MarketBeat
Aquatic Capital Management Boosts Vertex Pharmaceuticals Stake - National Today
Aquatic Capital Management LLC Acquires Shares of 29,596 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
S&P 500 Dips 0.21% as Vertex Pharmaceuticals Soars 8.31% Amid Market Struggles - Markets Mojo
Is Vertex Pharmaceuticals Heading to $600? - The Motley Fool
The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Chevy Chase Trust Holdings LLC - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Boosts Vertex Pharmaceuticals Stake - National Today
Banco Bilbao Vizcaya Argentaria S.A. Buys 4,464 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Ameriprise Financial Inc. - MarketBeat
Aristotle Atlantic Partners LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Alliancebernstein L.P. Acquires 144,266 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wellington Management Group LLP - MarketBeat
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.28%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):